                                                    Concept  PeriodEnd                                                                                                                                                                                                                                             Dims         Value
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                                                                                                                                   9.419300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                                                                                   8.882100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                                                                                   8.515900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.365900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.085400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.462000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.172100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.926000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.199000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember  2.538000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember  2.078100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember  1.766100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.492000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.887000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.266000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.588000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.277000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.085000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.082000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.467000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.435100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.167000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.744000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                             srt:ProductOrServiceAxis:jnj:ErleadaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.453000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                             srt:ProductOrServiceAxis:jnj:ErleadaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.282000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                             srt:ProductOrServiceAxis:jnj:ErleadaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.065000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                    srt:ProductOrServiceAxis:jnj:ErleadaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.121000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                    srt:ProductOrServiceAxis:jnj:ErleadaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.717000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                    srt:ProductOrServiceAxis:jnj:ErleadaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.322000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                       srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.574000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                       srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.999000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                       srt:ProductOrServiceAxis:jnj:ErleadaMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.387000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.020000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.051000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.931000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.018000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.214000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.823000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.038000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.264000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.570000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.410000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                srt:ProductOrServiceAxis:jnj:TECVAYLIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember  4.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                srt:ProductOrServiceAxis:jnj:TECVAYLIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember  4.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                srt:ProductOrServiceAxis:jnj:TECVAYLIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember  3.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                       srt:ProductOrServiceAxis:jnj:TECVAYLIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember  2.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                       srt:ProductOrServiceAxis:jnj:TECVAYLIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember  1.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                       srt:ProductOrServiceAxis:jnj:TECVAYLIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember  6.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                          srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember  6.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                          srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember  5.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                          srt:ProductOrServiceAxis:jnj:TECVAYLIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:PharmaceuticalMember  3.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.620000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.872000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.135500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.153900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.856000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.473000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.513000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember  1.572800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember  1.782800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember  1.805200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.171000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.009000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.143000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.768000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.605000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.839000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.193000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.082000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.124000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.475000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.108000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.073000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.668000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.190000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.197000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.847000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.720000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.966000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.230000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.641000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.892000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.078000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.036100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.085800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.529000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.443000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.147000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.626000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.227000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.990000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.155000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.670000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.147000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.151000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.398000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.065000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.686000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.718000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.076000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember  7.837000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember  7.115000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember  7.140000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                         srt:ProductOrServiceAxis:jnj:CAPLYTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                   srt:ProductOrServiceAxis:jnj:CAPLYTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.410000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.725000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.125000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.897000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.085000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.097000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.218000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.810000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.222000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.115000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.485000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.696000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.077000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.204000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.048000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.175000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.553000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.223000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.143000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.697000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.214000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.140000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.117000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember  4.437000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember  4.282000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember  3.815000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                srt:ProductOrServiceAxis:jnj:OPSUMITMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.633000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                srt:ProductOrServiceAxis:jnj:OPSUMITMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.557000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                srt:ProductOrServiceAxis:jnj:OPSUMITMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.292000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                       srt:ProductOrServiceAxis:jnj:OPSUMITMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                       srt:ProductOrServiceAxis:jnj:OPSUMITMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:ProductOrServiceAxis:jnj:OPSUMITMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                          srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.325000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                          srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.225000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                          srt:ProductOrServiceAxis:jnj:OPSUMITMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.973000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.536000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.511000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.326000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.902000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.817000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.582000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28             srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29             srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31             srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28    srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29    srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31    srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                       srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                       srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                       srt:ProductOrServiceAxis:jnj:OtherPulmonaryHypertensionMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.264000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.354000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.500000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.977000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.042000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.918000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember  3.241000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember  3.396000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember  4.418000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.461000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.241000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.115000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.486000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.272000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.150000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.226000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.311000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.446000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.010000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.579000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.712000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.854000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.010000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.395000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.414000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.175000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.866000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.906000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember  3.778000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember  3.562000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember  3.671000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.633000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.373000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.365000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.633000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.373000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.365000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.410000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.145000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.189000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.306000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.634400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.397000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.116900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.405700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.299400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.359000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.040100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.696400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.475900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.305000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.513000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.633000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.623000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.194000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.717000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember  8.928000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember  7.707000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember  6.350000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                        srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.891000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                        srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.738000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                        srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.458000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                               srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.743000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                               srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.529000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                               srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.230000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                  srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.634000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                  srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.267000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                  srt:ProductOrServiceAxis:jnj:ELECTROPHYSIOLOGYMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.688000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                  srt:ProductOrServiceAxis:jnj:AbiomedMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.393000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                  srt:ProductOrServiceAxis:jnj:AbiomedMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.213000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                  srt:ProductOrServiceAxis:jnj:AbiomedMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.066000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                         srt:ProductOrServiceAxis:jnj:AbiomedMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                         srt:ProductOrServiceAxis:jnj:AbiomedMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                         srt:ProductOrServiceAxis:jnj:AbiomedMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                            srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.751000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                            srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.496000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                            srt:ProductOrServiceAxis:jnj:AbiomedMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.306000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                     srt:ProductOrServiceAxis:jnj:ShockwaveMedicalInc.Member; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                     srt:ProductOrServiceAxis:jnj:ShockwaveMedicalInc.Member; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                            srt:ProductOrServiceAxis:jnj:ShockwaveMedicalInc.Member; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                            srt:ProductOrServiceAxis:jnj:ShockwaveMedicalInc.Member; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                               srt:ProductOrServiceAxis:jnj:ShockwaveMedicalInc.Member; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.146000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                               srt:ProductOrServiceAxis:jnj:ShockwaveMedicalInc.Member; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                      srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                      srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                      srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                             srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                             srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                             srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                srt:ProductOrServiceAxis:jnj:OtherCardiovascularMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.720000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.689000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.525000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.538000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.470000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.417000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember  9.258000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember  9.158000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember  8.942000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.080000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.057000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.674000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.638000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.560000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.587000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.545000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.456000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.058000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.013000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.949000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.088000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.036000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.030000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.146000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.049000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.979000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                           srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.658000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                           srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.696000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                           srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.684000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                  srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.193000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                  srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.230000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                  srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.263000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                     srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.852000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                     srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.926000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                     srt:ProductOrServiceAxis:jnj:SPINESPORTSOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.947000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.157000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.003000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.031000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.980000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.842000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.006000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember  1.013700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember  9.845000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember  1.003700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.900000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.838000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.833000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.678000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.650000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.837000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.577000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.488000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.671000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.258000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.165000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.198000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.302000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.192000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.168000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.560000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.358000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.366000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.225000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.128000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.086000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.243000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.018000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.986000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember  5.468000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember  5.146000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember  5.072000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.754000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.684000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.626000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.157000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.049000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.076000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.910000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.733000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.702000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.086000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.558000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.413000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.370000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.740800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.633200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.527500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.638400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.552500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.512500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.379200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.185700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.040000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  5.375200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  5.030200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  4.644400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember  4.044100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember  3.851900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember  3.871500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                                                                                                                                   9.419300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                                                                                   8.882100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                                                                                   8.515900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.040100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.379200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.696400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.185700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.475900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.040000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                             srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:country:US  5.375200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                             srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:country:US  5.030200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                             srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:country:US  4.644400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                       srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:srt:EuropeMember  2.153500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                       srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:srt:EuropeMember  2.021200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                       srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:srt:EuropeMember  2.041000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember  4.875000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember  4.714000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember  4.549000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                            srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember  1.403100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                            srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember  1.359300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                            srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember  1.375600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                                                                       srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember  9.419300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                       srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember  8.882100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                       srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember  8.515900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-28                                                                                                                                                                                                                                                   9.419300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-29                                                                                                                                                                                                                                                   8.882100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                                                                                                   8.515900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                                                                   2.399300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                                                                   2.247100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                                                                   6.962900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                                                                   6.630100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.468000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.816000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.866000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.835000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.060000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.565000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.652000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.450000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember  6.529000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember  5.380000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember  1.851900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember  1.528400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.072000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                            srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                   srt:ProductOrServiceAxis:jnj:CARVYKTIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.860000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.332000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                      srt:ProductOrServiceAxis:jnj:CARVYKTIMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.088000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.684000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.934000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                            srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.789000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.584000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.332000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.514000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                   srt:ProductOrServiceAxis:jnj:DARZALEXMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.797000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.672000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.016000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.044800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                      srt:ProductOrServiceAxis:jnj:DARZALEXMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.586000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                             srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                             srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                             srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.048000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                             srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                    srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                    srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                    srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.567000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                    srt:ProductOrServiceAxis:jnj:ERLEADAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.275000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                       srt:ProductOrServiceAxis:jnj:ERLEADAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.360000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                       srt:ProductOrServiceAxis:jnj:ERLEADAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.900000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                       srt:ProductOrServiceAxis:jnj:ERLEADAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.615000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                       srt:ProductOrServiceAxis:jnj:ERLEADAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.215000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.850000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                           srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.453000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                  srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.537000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.139000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                     srt:ProductOrServiceAxis:jnj:IMBRUVICAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.307000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.360000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.880000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                   srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                          srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.980000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                             srt:ProductOrServiceAxis:jnj:RYBREVANTLAZCLUZEMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                              srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                     srt:ProductOrServiceAxis:jnj:TALVEYMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                        srt:ProductOrServiceAxis:jnj:TALVEYMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                            srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                            srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                            srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                            srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                   srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                   srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                   srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                   srt:ProductOrServiceAxis:jnj:TecvayliMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                      srt:ProductOrServiceAxis:jnj:TecvayliMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.770000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                      srt:ProductOrServiceAxis:jnj:TecvayliMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                      srt:ProductOrServiceAxis:jnj:TecvayliMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                      srt:ProductOrServiceAxis:jnj:TecvayliMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                              srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                     srt:ProductOrServiceAxis:jnj:ZYTIGAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.130000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                        srt:ProductOrServiceAxis:jnj:ZYTIGAMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                       srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                              srt:ProductOrServiceAxis:jnj:OtherOncologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.360000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                 srt:ProductOrServiceAxis:jnj:OtherOncologyMember; us-gaap:SubsegmentsAxis:jnj:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.676000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.068000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.377000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                       srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.499000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.493000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.552000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.492000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                              srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.090000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember  4.168000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember  4.621000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember  1.186800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                 us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember  1.359000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                          srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                       srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:jnj:UNITEDSTATESExportsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.130000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                 srt:ProductOrServiceAxis:jnj:RemicadeMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.190000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.398000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                    srt:ProductOrServiceAxis:jnj:RemicadeMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.246000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.990000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.770000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.130000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                       srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.036000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                          srt:ProductOrServiceAxis:jnj:SimponiSimponiAriaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.607000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.022000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.770000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.081000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                           srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.021000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.768000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                  srt:ProductOrServiceAxis:jnj:StelaraMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.991000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.570000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.676000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.848000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                     srt:ProductOrServiceAxis:jnj:StelaraMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.012000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.910000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.384000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                           srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.789000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.181000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                  srt:ProductOrServiceAxis:jnj:TremfyaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.424000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.007000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.566000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                     srt:ProductOrServiceAxis:jnj:TremfyaMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.721000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                   srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                          srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  0.000000e+00
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                             srt:ProductOrServiceAxis:jnj:OtherImmunologyMember; us-gaap:SubsegmentsAxis:jnj:ImmunologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.367000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.094000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.712000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.250000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.620000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.011000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.090000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember  2.024000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember  1.755000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember  5.722000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember  5.340000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                         srt:ProductOrServiceAxis:jnj:CAPLYTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                         srt:ProductOrServiceAxis:jnj:CAPLYTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.510000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                   srt:ProductOrServiceAxis:jnj:CAPLYTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                   srt:ProductOrServiceAxis:jnj:CAPLYTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.510000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                         srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.010000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.520000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                   srt:ProductOrServiceAxis:jnj:CONCERTAMethylphenidateMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.021000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29             srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.329000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.040000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29    srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.049000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.824000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                       srt:ProductOrServiceAxis:jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.159000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.047000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                        srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.460000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                               srt:ProductOrServiceAxis:jnj:SPRAVATOMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.193000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                  srt:ProductOrServiceAxis:jnj:SPRAVATOMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.190000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                               srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                      srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                         srt:ProductOrServiceAxis:jnj:OTHERNEUROSCIENCEMember; us-gaap:SubsegmentsAxis:jnj:NeuroscienceMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.358000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                            srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.324000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember  1.115000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember  1.102000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember  3.253000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                      us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember  3.190000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                         srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                         srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                         srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.175000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                         srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.149000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                   srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                   srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                   srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.682000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                   srt:ProductOrServiceAxis:jnj:OPSUMITOPSYNVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.655000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.790000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.139000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.120000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                       srt:ProductOrServiceAxis:jnj:UPTRAVIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.411000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                          srt:ProductOrServiceAxis:jnj:UPTRAVIMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.352000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                  srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                  srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                  srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                  srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                         srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                         srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                         srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                         srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                            srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                            srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                            srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                            srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:PulmonaryHypertensionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                               srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.023000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.010000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.472000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                      srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.599000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember  8.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember  8.360000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember  2.434000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                         us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember  2.622000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                        srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.082000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29               srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.850000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.103000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                  srt:ProductOrServiceAxis:jnj:EDURANTrilpivirineMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29          srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.900000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29 srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.196000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                    srt:ProductOrServiceAxis:jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.305000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                   srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29          srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                             srt:ProductOrServiceAxis:jnj:OtherInfectiousDiseasesMember; us-gaap:SubsegmentsAxis:jnj:InfectiousDiseasesMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  7.130000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.381000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                    srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.061000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                           srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember  8.990000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember  8.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember  2.842000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                              us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember  2.605000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.946000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                        srt:ProductOrServiceAxis:jnj:XareltoMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.697000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.946000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                  srt:ProductOrServiceAxis:jnj:XareltoMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.697000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                          srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  3.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                 srt:ProductOrServiceAxis:jnj:OtherMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                    srt:ProductOrServiceAxis:jnj:OtherMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMetabolismOtherMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  9.402000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  8.871000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.665500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  2.499300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  6.161000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  5.709000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.798300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.763900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.556300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.458000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.463800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.263200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.306000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.148000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.931000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                              srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.292000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.190000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.698000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                     srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.353000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember  2.213000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember  1.966000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember  6.629000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                        us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:CardiovascularMember  5.645000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                           srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                           srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                           srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.145000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                           srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.057000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.980000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.190000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.064000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.889000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                     us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember  1.418000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                     us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember  1.279000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                     us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember  4.209000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                     us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ElectrophysiologyMember  3.946000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.360000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.035000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember  4.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember  3.620000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember  1.291000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:AbiomedMember  1.112000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                   srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.200000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                   srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                   srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                   srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                          srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember  2.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember  2.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember  8.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember  3.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                         srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember  9.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember  9.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember  3.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                   us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OtherCardiovascularMember  2.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.396000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.359000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.200000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.229000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.620000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.614000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember  2.274000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember  2.191000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember  6.820000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember  6.843000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.620000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                       srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.850000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                              srt:ProductOrServiceAxis:jnj:HIPSMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.235000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                 srt:ProductOrServiceAxis:jnj:HIPSMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.220000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                      srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                             srt:ProductOrServiceAxis:jnj:KNEESMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.770000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.520000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.155000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                srt:ProductOrServiceAxis:jnj:KNEESMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.147000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.515000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                     srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.499000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                            srt:ProductOrServiceAxis:jnj:TRAUMAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.860000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.333000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                               srt:ProductOrServiceAxis:jnj:TRAUMAMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.285000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                 srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                 srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                 srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.216000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                 srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.262000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                        srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                        srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                        srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                        srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                           srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.980000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                           srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                           srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.096000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                           srt:ProductOrServiceAxis:jnj:SPINEOTHERMember; us-gaap:SubsegmentsAxis:jnj:OrthopaedicsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.191000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.031000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.076000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                     srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.965000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.511000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.451000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.417000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                            srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.373000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember  2.542000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember  2.434000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember  7.493000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                               us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember  7.338000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.770000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.411000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                        srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.360000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.880000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  6.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.991000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                               srt:ProductOrServiceAxis:jnj:ADVANCEDMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.977000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.165000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.109000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.402000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                  srt:ProductOrServiceAxis:jnj:ADVANCEDMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.337000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.666000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                         srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.605000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.910000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.426000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                srt:ProductOrServiceAxis:jnj:GENERALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.397000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.378000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.325000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.092000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                   srt:ProductOrServiceAxis:jnj:GENERALMember; us-gaap:SubsegmentsAxis:jnj:SurgeryMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.001000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.694000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                      srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.619000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.510000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.354000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                             srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.224000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember  1.400000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember  1.300000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember  4.048000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember; us-gaap:SubsegmentsAxis:jnj:VisionMember  3.843000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.410000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.337000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                               srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.288000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.620000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  5.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.565000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                      srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.508000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.018000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  9.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.902000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                         srt:ProductOrServiceAxis:jnj:CONTACTLENSESOTHERMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.796000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                         srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:country:US; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.250000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                srt:ProductOrServiceAxis:jnj:SURGICALMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.330000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.147000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                   srt:ProductOrServiceAxis:jnj:SURGICALMember; us-gaap:SubsegmentsAxis:jnj:VisionMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.048000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.306000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.038000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.290200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                srt:StatementGeographicalAxis:country:US; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.210500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  4.124000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  3.853000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.208900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                       srt:StatementGeographicalAxis:us-gaap:NonUsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  1.156400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.430000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.891000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.499100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                          us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.366900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  1.370800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  1.290900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  3.955700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  3.709800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember  1.028500e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember  9.562000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember  3.007200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                srt:StatementGeographicalAxis:us-gaap:NonUsMember  2.920300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                                                                   2.399300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                                                                   2.247100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                                                                   6.962900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                                                                   6.630100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                    srt:StatementGeographicalAxis:country:US; srt:RestatementAxis:srt:RevisionOfPriorPeriodReclassificationAdjustmentMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29           srt:StatementGeographicalAxis:us-gaap:NonUsMember; srt:RestatementAxis:srt:RevisionOfPriorPeriodReclassificationAdjustmentMember; us-gaap:SubsegmentsAxis:jnj:ShockwaveMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember -2.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.556300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  8.430000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  1.458000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  7.891000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.463800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.499100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                   srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:InnovativeMedicineMember  4.263200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                              srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:jnj:MedTechMember  2.366900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  1.370800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  1.290900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  3.955700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                         srt:StatementGeographicalAxis:country:US  3.709800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                   srt:StatementGeographicalAxis:srt:EuropeMember  5.440000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                   srt:StatementGeographicalAxis:srt:EuropeMember  4.914000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                   srt:StatementGeographicalAxis:srt:EuropeMember  1.593700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                   srt:StatementGeographicalAxis:srt:EuropeMember  1.529100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                             srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember  1.231000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                             srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember  1.173000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                             srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember  3.604000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                             srt:StatementGeographicalAxis:jnj:WesternHemisphereExcludingUSMember  3.579000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                        srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember  3.614000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                        srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember  3.475000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                        srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember  1.053100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                        srt:StatementGeographicalAxis:jnj:AsiaPacificAfricaMember  1.033300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                                                                   2.399300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                                                                   2.247100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                                                                                                   6.962900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                                                                                                   6.630100e+10